Drugs - MedicineNews.net - Medical Updates

Search results for "Psoriasis"

Ixekizumab clears psoriasis in clinical trials

About 80% of patients with moderate to severe psoriasis saw their disease completely or almost completely cleared with Ixekizumab ( Taltz ), according to three large, long-term clinical trials led by ... read article

Symptoms of insomnia in psoriasis are directly mediated by pruritus and pain

Psoriasis is an immune-mediated chronic inflammatory disorder which manifests as dermatologic lesions, and psoriatic arthritis in about 30% of cases. Psoriasis is associated with multiple comorbid ... read article

Otezla for the treatment of patients with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy

Otezla ( Apremilast ) is an oral small-molecule inhibitor of phosphodiesterase 4 ( PDE4 ) specific for cyclic adenosine monophosphate ( cAMP ). PDE4 inhibition results in increased intracellular cAMP ... read article

Stelara is not recommended by NICE for treating active psoriatic arthritis

NICE ( National Institute for Health and Care Excellence ) has published final guidance today which does not recommend Ustekinumab ( Stelara ) for psoriatic arthritis. Psoriatic arthritis is an inf ... read article

Pediatric Crohn's disease: Humira approved in Europe

European Commission has approved Humira ( Adalimumab ) for the treatment of pediatric patients aged six to 17 years with severely active Crohn's disease who failed, are intolerant to or have contraind ... read article

Apremilast: clinical benefit in psoriatic arthritis

Celgene has announced that statistical significance for the primary endpoint of ACR20 at week 16 was achieved for patients receiving Apremilast 20 mg and 30 mg BID in both the PALACE-2 & 3 phase III s ... read article

A comparison between Stelara and Enbrel in management of moderate to severe psoriasis

Researchers at The University of Manchester ( UK ) have compared the drugs Etanercept ( Enbrel ) and Ustekinumab ( Stelara ), relatively new biological therapies that have proved effective in the man ... read article

Risk of tuberculosis with anti-TNF agents

Treatment with anti-tumor necrosis factor ( TNF ) agents is recognized as a risk factor for tuberculosis in patients with immune-mediated inflammatory diseases such as rheumatoid arthritis, ankylosing ... read article

Risk of histoplasmosis and other invasive fungal infections associated with Enbrel

Amgen Canada, on behalf of Immunex, in collaboration with Health Canada, has informed HealthCare Professionals of updated safety information regarding Enbrel ( Etanercept ). Enbrel is a soluble for ... read article

Risk of tuberculosis: higher for patients receiving anti-TNF monoclonal antibody therapy than for those receiving soluble TNF receptor therapy

Treatment with anti-TNF ( tumor necrosis factor ) blockers is recognized as a risk factor for tuberculosis ( TB ) in patients with immune-mediated inflammatory diseases such as rheumatoid arthritis, a ... read article

TNF blockers linked to increased risk of lymphoma, leukaemia and new-onset psoriasis

The FDA ( Food and Drug Administration ) is requiring the manufacturers of TNF blockers to update the Boxed Warning in the prescribing information to alert healthcare professionals of an increased ris ... read article

Genentech: voluntary withdrawal of Raptiva from the U.S. market

Genentech, the manufacturer of the psoriasis drug Raptiva ( Efalizumab ), announced that it has begun a voluntary, phased withdrawal of the product from the U.S. market. The company is taking this act ... read article

A case of progressive multifocal leukoencephalopathy in a Raptiva patient

Genentech announced that the company has issued a Dear Healthcare Provider letter to inform potential prescribers of a case of progressive multifocal leukoencephalopathy ( PML ) in a 70-year old patie ... read article

Raptiva associated with progressive multifocal leukoencephalopathy

Raptiva ( Efalizumab ) is an immunosuppressive, humanized monoclonal antibody indicated for treatment of adult patients with moderate to severe chronic plaque psoriasis who have failed to respond to, ... read article

Antibody to block the IL-22 cytokine; an innovative therapy for the human autoimmune disease, psoriasis

Researchers at King's College London have identified a new gene ( PIM1 ), which could be an effective target for innovative treatments and therapies for the human autoimmune disease, psoriasis.Psorias ... read article

Focus

Multiple sclerosis: FDA has approved Tecfidera

The FDA ( Food and Drug Administration ) has approved Tecfidera ( Dimethyl fumarate ) capsules to treat adults with relapsing forms of multiple sclerosis.Multiple sclerosis is a chronic, inflammatory, ... read article

Apremilast linked to significant and clinically meaningful improvements for the primary and major secondary endpoint in plaque psoriasis

Celgene has announced that statistical significance for the primary endpoint of PASI 75 at week 16 was achieved for patients receiving Apremilast 30 mg BID monotherapy in both the ESTEEM 1 and 2 phase ... read article

Kadcyla, a new treatment for late-stage breast cancer, approved by Food and Drug Administration

The U.S. Food and Drug Administration ) has approved Kadcyla ( Ado-Trastuzumab Emtansine ), a new therapy for patients with HER2-positive, late-stage ( metastatic ) breast cancer.HER2 is a protein inv ... read article

FISSION and NEUTRINO trial: Sofosbuvir has met primary endpoints for hepatitis C

Results from two Phase 3 studies, FISSION and NEUTRINO, evaluating a 12-week course of the once-daily nucleotide Sofosbuvir in combination with Ribavirin ( FISSION ) and in combination with Ribavirin ... read article

Increased risk of high-grade prostate cancer with 5-alpha reductase inhibitors

Men aged 55 and over with a normal digital rectal examination and PSA less than or equal to 3.0 ng/mL at baseline taking Finasteride 5 mg/day ( 5 times the dose of Propecia ) in the 7-year Prostate Ca ... read article

Castration-resistant prostate cancer: Cabozantinib linked to high rates of complete or partial bone scan resolution, pain relief, improvements in hemoglobin, and tumor regression

Exelixis has reported updated interim data from the cohort of patients with metastatic castration-resistant prostate cancer ( CRPC ) treated with Cabozantinib ( XL184; Cometriq ) in an ongoing phase 2 ... read article